Taking Wegovy with citalopram: what the evidence says

Semaglutide slows the time food and medicines spend in the stomach, which can theoretically alter the absorption rate of some oral drugs taken alongside it.
Citalopram is a selective serotonin reuptake inhibitor (SSRI); current prescribing guidance does not classify it as a drug whose absorption is clinically significantly affected by semaglutide.
Both semaglutide and citalopram carry individual warnings about QTc interval prolongation — a cardiac conduction measure — though the clinical significance of combining them depends on your personal cardiac history and other medicines.
Any change to either medicine while on Wegovy should be discussed with the prescriber who manages your weight treatment and, where relevant, the clinician prescribing the citalopram.

Wegovy (semaglutide) and citalopram are not known to have a direct pharmacokinetic interaction that would make the combination unsafe, but there are two things worth understanding before you take them together: how semaglutide slows gastric emptying, and what that can mean for the absorption of oral medicines. Both are prescription-only medicines requiring individual clinical assessment, so a prescriber who can see your full medication list is always the right starting point. Semaglutide's mechanism is central to understanding why this question comes up at all.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Citalopram, semaglutide and what current guidance actually tells prescribers

Where the concern about absorption comes from

The Summary of Product Characteristics for semaglutide, published on the electronic Medicines Compendium, notes that because the medicine delays gastric emptying, it has the potential to influence the absorption of orally administered drugs. This is not unique to Wegovy, it is a class effect of GLP-1 receptor agonists. In the clinical pharmacology studies conducted before licensing, semaglutide did not meaningfully alter the bioavailability of most tested oral medicines. Citalopram was not among the specifically studied drugs in those studies, so there is no published data showing a clinically significant absorption interaction. The practical implication is that the combination is not contraindicated in prescribing guidance, but it also has not been exhaustively tested in a head-to-head study. A prescriber reviewing your full medication history is best placed to weigh that gap against your individual circumstances. For context on the wider list of medicines that warrant more careful thought alongside semaglutide, the full drug interaction picture for Wegovy covers the areas where caution is formalised in the guidance.

The QTc question, real, but often overstated

One concern that circulates online is that citalopram raises the risk of a prolonged QTc interval, and that combining it with Wegovy compounds that risk. It is worth addressing directly: citalopram does carry a dose-dependent QTc warning, which is why the Medicines and Healthcare products Regulatory Agency updated citalopram's prescribing information some years ago and the maximum daily dose in many adults is now 40 mg. Semaglutide's product information does not list QTc prolongation as a known effect, so the two medicines are not additive on that measure in the way that, for example, two QTc-prolonging antiarrhythmics would be. That said, if you are on higher-dose citalopram, have a history of cardiac arrhythmia, or take other medicines that affect cardiac conduction, your prescriber needs to know before starting Wegovy. The medicines to avoid with semaglutide page explains the categories where interaction risk is more formally established.

Mental health and GLP-1 medicines: a nuance prescribers consider

There is a separate, broader point worth raising here. Wegovy's active ingredient and pharmacology primarily targets appetite and metabolism, but GLP-1 receptors are present in the brain as well as the gut, and the research on mood effects is still developing. Current UK prescribing guidance does not list depression or anxiety as a contraindication to semaglutide, nor does it flag a specific interaction with SSRIs. However, the MHRA's Yellow Card scheme remains the mechanism by which unexpected signals (including any new psychiatric symptoms noticed after starting a GLP-1 medicine) are collected and reviewed. If you are stable on citalopram and notice any change in mood after starting Wegovy, that is worth raising promptly with your prescriber rather than attributing it to one cause or the other. You can also report unexpected effects directly at the MHRA Yellow Card service. The NHS medicines page on semaglutide lists the known side-effect profile as assessed at licensing and is a reliable reference point for patients.

Practical steps before combining the two

If you are already taking citalopram and are considering Wegovy for weight management, the most important step is straightforward: list every medicine, including over-the-counter and herbal products, on your consultation form. A GPhC-registered Independent Prescriber reviews each consultation, every submission is read by a real clinician, not processed automatically. That review is where potential interactions, your cardiac history, and any relevant mental health background are factored in. If the prescriber has questions or needs to liaise with your GP, that happens before any prescription is issued. You might also find it useful to read about semaglutide alongside propranolol, since propranolol raises a related but different set of interaction considerations. On the question of cost, a clear explanation of what Wegovy costs through a private clinic may help you plan. When you are ready to discuss your personal medication list with our clinical team, you can start your free consultation and have that conversation with a prescriber the same day.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions